ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ピトリサント

Pitolisant

HCID 9948102
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
362665-56-3
標準SMILES
Clc1ccc(CCCOCCCN2CCCCC2)cc1
InChIKey
NNACHAUCXXVJSP-UHFFFAOYSA-N
分子式
C17H26ClNO
平均分子量
295.8 g/mol
単同位体質量
295.1702921

概要

Pitolisant is an organochlorine compound.

名称と識別子

優先名称
Pitolisant
IUPAC
1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine
現地名
ピトリサント
英語名
Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-
分子式
C17H26ClNO
分子量
295.85

名称と別名

Pitolisant362665-56-31-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidineTIPROLISANT1-(3-(3-(4-Chlorophenyl)propoxy)propyl)piperidineBF2.649HBS-1011-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine4BC83L4PIYBF-2649BF-2.649DTXSID30957654
名称をさらに表示
ピトリサント1-[3-[3-(4-クロロフェニル)プロポキシ]プロピル]ピペリジン1-{3-[3-(4-クロロフェニル)プロポキシ]プロピル}ピペリジン3-ピペリジノプロピル[3-(4-クロロフェニル)プロピル]エーテルTirolisantTilolisonPitolisomtTiprolisant PitolisantBF 2.649Chlorophenyl)propoxy)propyl)piperidine
N07XX11pitolisantumWakix, europeRefChem:57771DTXCID60207876Pitolisant (BF2.649)wakixMFCD18782650

データベース識別子

CAS
362665-56-3
PubChem CID
9948102
DTXSID
DTXSID30957654
ChEMBL
CHEMBL462605
ChEBI
CHEBI:134709
UNII
4BC83L4PIY
EC Number
111-217-6
Nikkaji
J1.574.747A

物性

構造計算による物性

XLogP
4.3
極性表面積
12.5 Ų
水素結合供与体数
0
水素結合受容体数
2
回転可能結合数
8
重原子数
20
形式電荷
0
複雑度
235

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
Human Drugs · 4 件

Breast Feeding; Lactation; Milk, Human; Histamine H3 Antagonists; Wakefulness-Promoting Agents

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine (Orphan designations)

EMA approved medicines: Human medicine

物理化学的性質

沸点
398.7 · 398.7±32.0 °C(Predicted)
比重(密度)
1.056 · 1.056
貯蔵温度
-20 °C · Sealed in dry,Store in freezer, under -20°C
溶解性
DMSO
外見
Powder
酸解離定数(Pka)
9.41 · 9.41±0.10(Predicted)
色
Colorless to light yellow

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H361fd (100%): Suspected of damaging fertility; Suspected of damaging the unborn child [Warning Reproductive toxicity]

P203, P280, P318, P405, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

危険有害性情報

Hazard Classes and CategoriesRepr. 2 (100%)

毒性情報

Hepatotoxicity · 1 件

In placebo-controlled trials of pitolisant in patients with narcolepsy, minor serum aminotransferase elevations occurred in a small proportion of patients during therapy, but rates of enzyme elevations were similar to those in placebo recipients. In preregistration trials, there were no instances of clinically apparent liver injury or serum aminotransferase elevations with jaundice attributable to pitolisant. Since its approval in Europe in 2017 and the United States in 2020, there have been no publications describing clinically apparent liver injury due to pitolisant.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード H315

化学と産業

薬理情報

ATC Code · 2 件

N - Nervous system

QN - Nervous system

Protein BindingThe serum protein binding of pitolisant is approximately 91% to 96%. Pitolisant is mainly bound to serum albumin and alpha-1 glycoprotein.
Pharmacodynamics · 1 件

Pitolisant promotes wakefulness in narcolepsy by enhancing histaminergic signalling in the central nervous system. It does not significantly bind to H1, H2, or H4 receptors. In patients with narcolepsy in presence or absence of cataplexy, treatment of pitolisant was associated with an improvement in the level and duration of wakefulness and daytime alertness assessed by objective measures of ability to sustain wakefulness (e.g. Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) Scores) and attention (e.g. Sustained Attention to Response Task (SART)). Pitolisant also improved the frequency and severity of narcolepsy-associated cataplexy. Pitolisant acts as a blocker at hERG channels. In two QT studies, supra-therapeutic doses of pitolisant (3-6-times the therapeutic dose, that is 108 mg to 216 mg) produced mild to moderate prolongation of QTc interval (10-13 ms).

Mechanism of Action · 1 件

Signalling of histaminergic neurons plays a key role in activating the arousal system with widespread projections to the whole brain via activating orexin receptors. Narcolepsy is characterized by insufficient neurotransmission by orexins, or hypocretins, which are excitatory peptides released by neurons located from the lateral hypothalamus. These neurons project to aminergic neurons, such as histaminergic or noradrenergic neurons, that are responsible for the effects of orexin and control of wakefulness. Histamine H3 receptors are presynaptic inhibitory autoreceptors that are located in the cerebral cortex, hypothalamus, hippocampus, and basal ganglia. H3 receptors promote the re-uptake of histamine at synaptic terminals and attenuate further histamine release into the synapse. By blocking H3 autoreceptors and increasing the levels of histamine transmitters at the synapse, pitolisant enhances the activity of histaminergic neurons and promotes wakefulness. Inverse agonism of pitolisant at H3 receptors also leads to enhanced synthesis and release of endogenous histamine over the basal level. Pitolisant acts as a high-affinity competitive antagonist (Ki 0.16 nM) and as an inverse agonist (EC50 1.5 nM) at the human H3 receptor and mediates its pharmacological action at the presynaptic level. It is thought to bind to the antagonist binding site of the H3 receptor, which is located within the transmembrane core just below the extracellular loops. Piperidines form a salt bridge with Glu206 in the membrane-spanning segment, and the hydroxyl of Tyr374 is H-bonded with the central oxygen of piperidine. Pitolisant displays high selectivity for H3 receptors compared to other histamine receptor subtypes. Pitolisant also modulates acetylcholine, noradrenaline and dopamine release in the brain by increasing the levels of neurotransmitters but does not increase dopamine release in the stratal complex, including the nucleus accumbens. At lower nanomolar concentrations, pitolisant acts as an inverse agonist at H3 receptors and enhances the release of endogenous histamine over the basal level.

関連反応

6 件
反応記録を作成
HRID 121161 の反応式
HRID 121161生成物として
HRID 222215 の反応式
HRID 222215生成物として
HRID 604383 の反応式
HRID 604383生成物として
HRID 1376166 の反応式
HRID 1376166生成物として
HRID 1804758 の反応式
HRID 1804758生成物として
HRID 2329564 の反応式
HRID 2329564生成物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
Biological Half-LifePitolisant has a plasma half-life of 10-12 hours. After administration of a single dose of 35.6 mg, the median half-life of pitolisant was approximately 20 hours.
Metabolism/Metabolites · 1 件

Pitolisant is primarily metabolized by CYP2D6 and to a lesser extent by CYP3A4 in the liver. The major non-conjugated metabolites are BP2.941 (piperidine N-oxide) and BP2.951 (5-aminovaleric acid). Metabolites can further undergo conjugation with glycine or glucuronic acid, and oxidation to a minimal extent. Most metabolites of pitolisant do not retain considerable pharmacological activities. Several conjugated metabolites were also identified; the major conjugated inactive metabolite was a glycine conjugate of the acid metabolite of O-dealkylated desaturated pitolisant and a glucuronide of a ketone metabolite of monohydroxy desaturated pitolisant. Due to its extensive metabolism in the liver, the systemic exposure of pitolisant thus adverse events of the drug may be elevated in case of compromised liver function. The dosage adjustments for pitolisant is advised in patients with moderate hepatic impairment.

FDA Pharmacological Classification · 6 件

4BC83L4PIY

PITOLISANT

Established Pharmacologic Class [EPC] - Histamine-3 Receptor Antagonist/Inverse Agonist

Mechanisms of Action [MoA] - Histamine H3 Receptor Inverse Agonists

Mechanisms of Action [MoA] - Histamine H3 Receptor Antagonists

Mechanisms of Action [MoA] - Cytochrome P450 3A4 Inducers

Absorption, Distribution and Excretion · 4 件

Pitolisant is rapidly and well absorbed following oral administration, resulting in the drug being 90% absorbed. In healthy individuals receiving an oral dose of 20 mg, the Cmax was approximately 30 ng/mL. Following oral administration of pitolisant 35.6 mg once daily, the mean steady state Cmax and AUC were 73 ng/mL and 812 ngxhr/mL, respectively. The Tmax was typically reached approximately 3 hours following administration. Following repeated dosing, the steady-state plasma concentration is achieved after 5-6 days of administration but the inter-individual variability in the time to reach steady-state is reported to be high. The absolute bioavailability of pitolisant has not been determined.

Following hepatic metabolism, about 63% of total elimination occurs via renal excretion into the urine as an inactive non-conjugated metabolite BP2.951 and a glycine conjugated metabolite. About 25% of the total dose administered is excreted through expired air as metabolites, and a small fraction (<3%) of drug can be recovered in faeces.

Following single and multiple oral dosing of pitolisant to healthy male adults at doses between 1 and 240 mg, the apparent volume of distribution (V/F) ranges from 1100 to 2825 L. Pitolisant is thought to be equally distributed between red blood cells and plasma. Following intravenous administration of pitolisant in rats and monkeys, the apparent Vd at steady-state was approximately 10-fold greater than total body water. Pitolisant crosses the blood-brain barrier and placenta, and was found in milk in rats.

The apparent oral clearance (CL/F) of pitolisant was 43.9 L/hr following a single dose of 35.6 mg. The clearance rate is expected to be lower with increasing age.

応用分野 · 1 件

使用Pitolisant is a potent and selective nonimidazole inverse agonist at the recombinant human histamine H3 receptor. Pitolisant is also used in the treatment of patients with narcolepsy, excessive daytime sleepiness, cataplexy, disturbed nocturnal sleep, hypnagogic hallucinations and sleep paralysis